Jazz Pharma Begins Trial of Erwinaze; Merck Begins Phase II/III Study of MK-8931 Print E-mail
By Staff and Wire Reports   
Monday, 03 December 2012 19:44
Below is a look at some of the headlines for companies that made news in the healthcare sector on December 3, 2012.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ)
announced the first patient has been enrolled and dosed in a clinical trial of Erwinaze® (asparaginase Erwinia chrysanthemi) administered intravenously (IV) as an alternative method of administration to treat patients with acute lymphoblastic leukemia (ALL) with hypersensitivity to E. coli-derived asparaginase therapy.


======


Merck (NYSE: MRK)
, known as MSD outside the United States and Canada, announced it has started a Phase II/III clinical trial designed to evaluate the safety and efficacy of MK-8931 versus placebo in patients with mild-to-moderate Alzheimer's disease. MK-8931 is Merck's novel investigational oral β-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor, and is the first with this mechanism to advance to this stage of clinical research.

The global, multi-center study, called EPOCH, is designed to initially evaluate the safety of MK-8931 in a cohort of 200 patients prior to advancing into a larger Phase III study.


Also Monday:



Advanced Cell Technology, Inc. (OTCBB: ACTC)
, a leader in the field of regenerative medicine, announced today that the company is a sponsor of the 2012 World Stem Cell Summit , Dec. 3-5 at the Palm Beach County Convention Center in West Palm Beach, Florida.

Advaxis, Inc., (OTCBB: ADXS)
, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that Thomas A. Moore, Chairman & CEO of Advaxis, will present at the NYC MedTech Program, a medical technology and life science forum founded by John Lieberman CPA, Managing Director of Perelson Weiner LLP.

ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX)
today announced the launch of its redesigned and updated corporate website,www.adventrx.com.

Alimera Sciences, Inc. (Nasdaq: ALIM)
("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, president and chief executive officer, will present at the Oppenheimer 23rd Annual Healthcare Conference at 4:30 P.M. ET on Wednesday, December 12, 2012 at The Waldorf Astoria Hotel in New York City.

Alkermes plc (NASDAQ: ALKS)
today announced that data on three of the company’s clinical programs are scheduled to be presented at two upcoming major medical meetings this week. At the Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Hollywood, Fla., Dec. 2-6, 2012, Alkermes will present pharmacokinetic data on ALKS 9070, a new chemical entity currently in phase 3 development for the treatment of schizophrenia.

Amarantus Bioscience, Inc. (OTCQB: AMBS)
, a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it has completed a name change from Amarantus Biosciences, Inc. to Amarantus Bioscience, Inc.

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA)
today announced the presentations on ponatinib, its investigational BCR-ABL inhibitor, that will take place at the 54th Annual Meeting of the American Society of Hematology (ASH) being held in Atlanta, December 8 to 11, 2012.

AVEO Oncology (NASDAQ: AVEO)
and Astellas Pharma Inc. (TSE: 4503) today announced the initiation of patient enrollment in a randomized, double-blind, multicenter Phase 2 clinical trial, called BATON-BC, evaluating the efficacy of tivozanib, an investigational drug, in combination with paclitaxel compared to placebo in combination with paclitaxel in patients with locally recurrent or metastatic triple negative breast cancer who have received no prior systemic therapy for advanced or metastatic breast cancer (mBC).

BIOLASE, Inc. (NASDAQ: BIOL)
, the world's leading dental laser manufacturer and distributor, announced today that its Board of Directors has declared a one-half percent stock dividend payable on December 28, 2012, to stockholders of record on December 14, 2012.

Cellceutix Corporation (OTCBB: CTIX)
(the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, is pleased to report that clinical trials for Kevetrin™, the Company's flagship anti-cancer drug, are progressing smoothly.

CollabRx, Inc. (NASDAQ: CLRX)
, a data analytics company focused on genomics, today announced that it is scheduled to present at LD MICRO’s 5th Annual Conference on Thursday, December 6, 2013, at 10 a.m. Pacific Standard Time.

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST)
today announced that company management will discuss Cubist’s business activities and financial outlook at the Oppenheimer 23rd Annual Healthcare Conference in December 2012.

Diagnostic Imaging International Corp. (OTCQB:DIIG) (PINKSHEETS:DIIG) is pleased to announce that it has entered into an amendment of the Share Purchase Agreement with the owners of an MRI facility (the "Facility") that was originally agreed to on August 13, 2012.

eHealth, Inc. (NASDAQ: EHTH)
published an updated Medicare Resource Guide to help consumers find, compare and enroll in the quality Medicare coverage they need. The first wave of the baby boom generation, the 78 million Americans born between 1946 and 1964 and alive as of 2005, began turning age 65 and becoming eligible for Medicare in 2011.

Emergent BioSolutions Inc. (NYSE: EBS)
announced today that a member of the company’s senior management team will provide a corporate overview presentation at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 8, 2013 at 10:00AM Pacific.

Forest Laboratories, Inc. (NYSE: FRX)
today announced it will be presenting data on cariprazine at the American College of Neuropsychopharmacology Annual Meeting scheduled December 2-6, 2012 in Hollywood, FL.

Grass Roots Research & Distribution Inc. (GRRD), Wall Street's leading independent micro-cap research firm, has announced that it has initiated coverage on Ingen Technologies Inc. (PINKSHEETS: IGNT) with a STRONG BUY recommendation and a 12-month price target of $.15 per share.

ICON plc. (NASDAQ:ICLR)
(ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, is hosting an Investor Day in New York tomorrow, 4th December 2012.

ImmunoGen, Inc. (NASDAQ: IMGN)
, a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that there will be clinical data presentations on two compounds that utilize the Company’s TAP technology at the 54th annual meeting of the American Society of Hematology (ASH) to be held December 8-11, 2012 in Atlanta, GA.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ)
today announced that the first patient has been enrolled and dosed in a clinical trial of Erwinaze® (asparaginase Erwinia chrysanthemi) administered intravenously (IV) as an alternative method of administration to treat patients with acute lymphoblastic leukemia (ALL) with hypersensitivity to E. coli-derived asparaginase therapy.

Lpath, Inc. (NASDAQ: LPTN)
, the industry leader in bioactive lipid-targeted therapeutics, ranked eighth among biotechnology and pharmaceutical companies and 60th overall on the 2012 Technology Fast 500™, Deloitte's ranking of 500 of the fastest growing life sciences, technology, media, telecommunications and clean technology companies in North America.

Merck (NYSE: MRK)
, known as MSD outside the United States and Canada, announced it has started a Phase II/III clinical trial designed to evaluate the safety and efficacy of MK-8931 versus placebo in patients with mild-to-moderate Alzheimer's disease.

MMRGlobal, Inc. (OTCQB: MMRF)
("MMR") today announced that it has received a Notice of Allowance, U.S. Serial No. 13/352,068, from the United States Patent and Trademark Office which further expands the Company's "Method and System for Providing Online Medical Records."

Monar International Inc. (OTCQB:MNAI)
is proud to announce that it has entered into a Strategic Alliance and Distribution Agreement for M-Fuel with EcoloCap Solutions of Chicago.

PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI)
today announced that Bruce Tomlinson has resigned his position as vice president and chief financial officer of PDL due to personal reasons.  His resignation is effective as of November 30, 2012.

Pressure BioSciences, Inc. (OTCQB: PBIO)
("PBI" or the "Company") today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview at the 5th Annual LD MICRO Growth Conference on Thursday, December 6th at 2:30 PM PST.

PURE Bioscience, Inc. (NASDAQ: PURE)
, the creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that Chief Executive Officer Michael L. Krall and Chief Financial Officer Peter C. Wulff are scheduled to present to investors at the 5th Annual LD Micro Growth Conference on Thursday, December 6, 2012 at 9:00 a.m. Pacific Time.

Synthetic Biologics, Inc. (NYSE MKT: SYN)
, a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that the Company closed the previously announced deal with Prev AbR LLC (Prev) and acquired a series of beta-lactamase compounds (P1A, P2A and P3A) and related assets targeting the prevention of Clostridium difficile(C. diff)infection.

Therapeutic Solutions International, Inc. (OTCQB: TSOI)
, announced today that it has recently completed all of its regulatory filings required by the Securities and Exchange Commission, and that it is now 'fully reporting' and compliant.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)
announced today that Health Canada has approved KALYDECOTM (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF), for people ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

VistaGen Therapeutics, Inc. (OTCBB: VSTA)
, a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, has formalized its membership in the Toronto-based Centre for Commercialization of Regenerative Medicine's (CCRM) Industry Consortium.

YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM)
today reported that CIMYM BioSciences Inc. has sold its assets relating to nimotuzumab to InnoKeys PTE Ltd., a company based in Singapore, for undisclosed consideration including an immediate US$2 million payment. CIMYM was a joint venture subsidiary 80% owned by YM BioSciences and 20% owned by CIMAB S.A. (representing Centro de Inmunología Molecular, Cuba).



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter